Neuronetics (Nasdaq:STIM) announced today that it agreed to acquire all outstanding shares of Greenbrook TMS in an all-stock transaction. The acquisition creates a vertically integrated organization comprised of two companies that develop transcranial magnetic stimulation (TMS) technology. Malvern, Pennsylvania–based Neuronetics develops products aimed at improving the lives of patients with neurohealth disorders. Its NeuroStar technology […]
Neuronetics
FDA clears Neuronetics’ neurostim for adolescents with depression
Neuronetics (Nasdaq:STIM) announced today that it received FDA clearance for the use of its NeuroStar therapy for adolescent patients. Clearance covers the use of NeuroStar as an adjunct treatment of major depressive disorder (MDD) in adolescent patients aged 15-21. Neuronetics said clearance makes NeuroStar the first and only transcranial magnetic stimulation (TMS) treatment cleared for […]
Aetna policy update expands access to Neuronetics NeuroStar
Neuronetics (Nasdaq:STIM) announced today that a healthcare policy update from Aetna increases access to its NeuroStar therapy. Malvern, Pennsylvania-based Neuronetics develops products aimed at improving the life of patients with neuro health disorders. NeuroStar, a non-drug, non-invasive treatment can improve the quality of life for neuro health patients when traditional medication fails. The transcranial magnetic […]
FDA clears OCD cap from Neuronetics
Neuronetics (Nasdaq:STIM) announced today that it received FDA 510(k) clearance for its obsessive-compulsive disorder MT cap. The FDA cleared the company’s OCD motor threshold (MT) cap technology for NeuroStar advanced therapy for mental health. According to a news release, determining a patient’s MT represents a critical step to establishing their prescription before starting treatment. NeuroStar, […]
Neuronetics enhances NeuroStar connectivity with Wi-Fi capabilities
Neuronetics (Nasdaq:STIM) announced that it implemented improved internet connectivity capabilities across its NeuroStar platform. Malvern, Pennsylvania-based Neuronetics develops products aimed at improving the life of patients with neuro health disorders. Its latest updates to NeuroStar particularly improve connectivity for providers with restricted networks. NeuroStar, a non-drug, non-invasive treatment can improve the quality of life for […]
Neuronetics shares rise on Street-beating Q3 results
Neuronetics (NSDQ:STIM) this week posted third-quarter results that beat the consensus on Wall Street. The Malvern, Pennsylvania-based psychiatric disorder treatment developer reported a net loss of $7.6 million, or -28¢ per share, on sales of $16.5 million for the three months ended Sept. 30, on sales growth of 19.56% compared with Q3 2021. Earnings per share […]
FDA clears Neuronetics’ motor threshold detection tech
Neuronetics (Nasdaq:STIM) announced today that it received FDA 510(k) clearance for its D-Tect MT accessory for the NeuroStar platform. Malvern, Pennsylvania-based Neuronetics designed its D-Tect accessory to simplify the motor threshold (MT) determination for physicians. According to a news release, the now FDA-cleared technology gives clinicians a way to determine MT by visually reporting the […]
Neuronetics stock rises on Street-beating Q2
Neuronetics (Nasdaq:STIM) shares ticked up today on second-quarter results that beat the consensus forecast. The Malvern, Pennsylvania-based company posted losses of $10.4 million, or 39¢ per share, on sales of $16.3 million for the three months ended June 30, 2022, for a bottom-line deeper into the red on sales growth of nearly 15%. Neuronetics’ losses […]
Neuronetics inks deal with Alleviant to supply NeuroStar to mental health clinics
Neuronetics (Nasdaq:STIM) announced today that it entered into a commercial partnership with Alleviant Health Centers. Under the agreement, Malvern, Pennsylvania-based Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics. According to a news release, an initial six NeuroStar advanced therapy systems — Neuronetics’ non-drug, non-invasive treatment […]
FDA clears Neuronetics’ therapy for anxious depression
Neuronetics (Nasdaq:STIM) announced today that the FDA cleared a new indication for its transcranial magnetic stimulation (TMS) system. The new indication for the NeuroStar advanced therapy for mental health allows the system to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression. NeuroStar is a non-drug, […]
Neuronetics ticks up before hours on mixed-bag Q1 results
Neuronetics (NSDQ:STIM) posted first-quarter results today that beat the revenue consensus on Wall Street and matched on earnings. The Malvern, Pa.-based company reported losses of -$7.9 million, or -31¢ per share, on sales of $12.3 million for the three months ended March 31, 2021, for a sales growth of 7.08% compared with Q1 2020. Earnings per […]
